Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Proliferation of Lifestyle Diseases Augments Prospects for the Cardiovascular Drugs Market in Saudi Arabia and the UAE Finds Frost & Sullivan - Expanding base of ageing population fuels market growth - Pharma.Frost.com
Proliferation of Lifestyle Diseases Augments Prospects for the Cardiovascular Drugs Market in Saudi Arabia and the UAE Finds Frost & Sullivan

 

PRZOOM - /newswire/ - Dubai, UAE, United Arab Emirates, 2011/11/09 - Expanding base of ageing population fuels market growth - Pharma.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The high incidence of lifestyle diseases, including obesity, hypertension and diabetes, in the UAE is the key factor driving growth in the cardiovascular drugs market. In the Kingdom of Saudi Arabia (KSA), the prominent growth drivers are the demographic shift toward baby boomers, the increasing incidence of cardiovascular diseases and mandatory health insurance for expatriate employees.

The cardiovascular drugs market in KSA witnessed double-digit growth from 2007 to 2010. The total pharmaceutical market in the UAE generated revenue of USD$1.3 billion, in 2010 and cardiovascular drugs contributed around 7.5 per cent of the total market revenue.

New analysis from Frost & Sullivan (pharma.frost.com), Analysis of Cardiovascular Drugs Market in Saudi Arabia and the United Arab Emirates, finds that the KSA and UAE markets earned revenue of USD $100.2 million and USD $172.8 million in 2010 and are expected to grow at a CAGR of 16.5 per cent and 17.6 per cent to reach USD $291.4 million and USD $537.1 million in 2017, respectively.

"Within the cardiovascular drugs market, antihypertensives held the largest share of almost 60 per cent of the revenue in 2010, followed by antidyslipidemics (lipid lowering), which held a 37 per cent share," says Frost & Sullivan Pharmaceuticals Research Analyst. "The 'other' segment held a share of around three per cent."

Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs) within the antihypertensives segment are the most preferred drugs in both the markets. Statins are the most-used drug class among antidyslipidemics in both markets.

The patent expiry of the key innovative molecules, stringent regulatory processes and government's encouragement of generics along with low patient compliance in the cardiovascular segment are the growth bottlenecks in the cardiovascular markets in KSA and UAE. In particular, many cardiovascular drugs including blockbusters will soon be off-patent and such expiries are not being replaced with new molecules.

"The government is patronizing generics to control spiralling healthcare and support the domestic pharmaceutical companies," observes the Analyst. "Although genericization is expected to propel consumption of medicines, it is likely to negatively impact the market size in terms of value."

Going forward, all three market segments - antihypertensive, lipid lowering and others (including multi-therapy combination drugs) are expected to grow. Identifying and targeting the right molecule within the market segments will ensure strong business traction.

Growth in the lipid-lowering drugs segment is expected to outpace that in the other segments. Their proportionate contribution to the total cardiovascular drugs market is likely to increase due to the higher incidence of dyslipidemia and modifications of guidelines for normal low density lipoprotein (LDL) level from 120mg/dl to 100mg/dl.

If you are interested in more information on this study, please send an email with your contact details to Deepshri Iyer/ Nimisha Iyer Corporate Communications, at deepshrii[.]frost.com/ niyer[.]frost.com with your full name, company name, title, telephone number, company email address, company website, city, state and country.

Analysis of Cardiovascular Drugs Market in Saudi Arabia and the United Arab Emirates is part of the Pharmaceuticals & Biotechnology Growth Partnership Service program, which also includes research in the following markets: European Diabetes Therapeutics Market, 2011 U.S. Diabetes Injection Pens Features and Global CRO Market: Quantitative Assessment. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

Analysis of Cardiovascular Drugs Market in Saudi Arabia and the United Arab Emirates
P51B-52

Contact:
Tanu Chopra, Corporate Communications - Middle East and North Africa
P: +91 22 6607 2037 / F: +91 22 2832 4713 / E: tanu.chopra[.]frost.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Proliferation of Lifestyle Diseases Augments Prospects for the Cardiovascular Drugs Market in Saudi Arabia and the UAE Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Deepshri Iyer / Nimisha Iyer 
+91 22 6607 2038 / +91 98200 50519 deepshrii[.]frost.com / niyer[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  MagLar, Inc.

Visit  RightITnow Ltd

Visit  NAKIVO, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today